Progress in Neuro-Psychopharmacology and Biological Psychiatry
The therapeutic potential of bromocriptine in neuropsychological rehabilitation of patients with acquired brain damage
References (103)
The role of dopamine in locomotor activity and learning
Brain Res. Rev.
(1983)- et al.
Akinesia: a syndrome common to Parkinsonism, retarded depression, and negative symptoms of schizophrenia
Compr. Psychiatry
(1992) - et al.
Dopamine receptors in human brain: autoradiographic distribution of D2 sites
Neuroscience
(1989) - et al.
Psychopharmacologic management of traumatic brain injury
- et al.
Apomorphine has a therapeutic effect on neglect produced by unilateral dorsomedial prefrontal cortex lesions in rats
Exp. Neurol.
(1986) - et al.
Akinetic mutism: pharmacologic probe of the dopaminergic mesencephalofrontal activating system
Pediatr. Neurol.
(1988) Dopamine-mediated mechanisms of the prefrontal cortex
Semin. Neurosci.
(1992)- et al.
Bromocriptine treatment of nonfluent aphasia
Arch. Phys. Med. Rehabil.
(1992) - et al.
Chronic treatment with bromocriptine induces behavioral supersensitivity in rats
Life Sci.
(1986) - et al.
Bromocriptine for “negative” schizophrenia
Compr. Psychiatry
(1991)
Cholinergic-dopaminergic interactions in cognitive performance
Behav. Neural Biol.
Schizophrenia and the D1 receptor: focus on negative symptoms
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
Reliability and validity of the apathy evaluation scale
Psychiatry Res.
The sources of convergence between measures of apathy and depression
J. Affect. Disord.
Antidepressant-like effects of dopamine agonists in an animal model of depression
Biol. Psychiatry
Pharmacotherapy for aphasia
Neurology
Pharmacotherapy of nonfluent aphasia
Neurology
Relief of akinetic mutism from obstructive hydrocephalus using bromocriptine and ephedrine: case report
J. Neurosurg
Ethicolegal issues in pharmacotherapy for neurorehabilitation
NeuroRehabilitation
The role of pharmacotherapy in the treatment of aphasia: preliminary results
Aphasiology
Biological and psychosocial factors in recovery from brain damage in humans
Can. J. Psychol.
Treating organic abulia with bromocriptine and lisuride: four case studies
J. Neurol. Neurosurg. Psychiatry
Pleuropulmonary disease associated with dopamine agonist therapy
Ann. Neurol.
Effects of bromocriptine in human narcolepsy
Clin. Neuropharmacol.
Selective D-1 dopamine receptor agonist treatment of Parkinson's disease
J. Neural Transm.
Bromocriptine in parkinsonism
Br. Med. J.
Successfull treatment of akinetic mutism with a post synaptic dopamine agonist
Arch. Phys. Med. Rehabil.
Pharmacological treatment of posttraumatic behavioral disorders: aggression and disorders of mood
Compulsive pre-sleep behavior and apathy due to bilateral thalamic stroke: response to bromocriptine
Neurology
Brain networks underlying personality development
Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease
Brain
Traumatic mutism and the subsequent reorganisation of speech functions
Neuropsychologia
Neuropsychologische Rehabilitation
The effect of bromocriptine on speech dysfunction in patients with diffuse brain injury (akinetic mutism)
Clin. Neuropharmacol.
Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients
Ann. Neurol.
Akinetic mutism in an bone marrow transplant recipient following total-body irridation and amphotericin B chemoprophylaxis: a positron emission tomographic and neuropathologic study
Arch. Neurol.
Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation
Eur. J. Clin. Pharmacol.
The use of Sinemet and bromocriptine
Brain Inj.
Effects of a selective D1 agonist, CY 208-243, in de novo patients with Parkinson disease
Mov. Disord.
The role of bromocriptine in the treatment of parkinsonism
Neurology
Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET
Science
Amphetamine, haioperidol, and experience interact to affect the rate of recovery after motor cortex injury
Science
Pharmacotherapy for recovery of function after brain injury
CRC Crit. Rev. Neurobiol.
Abulia minor vs. agitated behavior
Clin. Neurosurg.
Dopamine agonist therapy for neglect in humans
Neurology
2-Br-α-ergokryptin: Beeinflussung von Fertilität und Laktation bei der Ratte
Experientia
Studies on central D1 receptors role in volume transmission, neuroendocrine regulation and release of noradrenaline
Differential behavioral and biochemical effects of four dopaminergic agonists
Psychopharmacology
Molecular characterization of the dopamine transporter
Trends Pharmacol. Sci.
Cited by (48)
Apathy following traumatic brain injury: A review
2018, NeuropsychologiaCitation Excerpt :The role of mesolimbic dopamine for translating motivation into action has long been recognised (Mogenson et al., 1980) and more recently DA depletion has been considered a paradigm for understanding a wide range of deficits in TBI (Bales et al., 2009; Yan et al., 2015). Clinically, dopamine-based medication has been used for some time for treating a wide range of arousal, motivational and executive disorders in TBI despite lack of good evidence for so doing (Barrett, 1991; Muller and Von Cramon, 1994; Whyte et al., 2002). Anecdotal reports of benefit suggest this trend will continue but better quality trials are needed.
Apathy Following Traumatic Brain Injury
2014, Psychiatric Clinics of North AmericaCitation Excerpt :All of them included either single patients or small samples, and proper randomized-controlled trials (RCTs) that are adequately powered are still lacking. Muller and von Cramon49 used bromocriptine in 15 patients with TBI with behavioral problems, including apathy, but results were heterogeneous. Gualtieri and Evans50 treated 15 patients with methylphenidate in the context of a small controlled trial and noted significant short-term improvements in apathy.
Chapter 12 The dysexecutive syndromes
2008, Handbook of Clinical NeurologyCitation Excerpt :Dopaminergic agents (e.g., pramipexole, bromocriptine, selegiline, L-dopa) are most often prescribed for the treatment of Parkinson's disease. However, these medications also have been used to help improve motivation, diminish apathy, and to augment working memory and other executive functions (Luciana et al., 1992; Muller and von Cramon, 1994; Marin et al., 1995; Luciana and Collins, 1997; McDowell et al., 1998; Muller et al., 1998). Interestingly, in neurologically healthy individuals, activation of D1 dopamine receptors may be more important than activation of D2 receptors and dopamine agonists may be more effective in improving working memory performance in those individuals who have a low working memory capacity than those with high working memory capacity (Kimberg et al., 1997; Muller et al., 1998).
Chapter 14 Aphasia
2008, Handbook of Clinical NeurologyCitation Excerpt :Benefit was not lost when treatment was stopped. Numerous case reports of benefit with bromocriptine (Albert et al., 1988; MacLennan et al., 1991; Muller and von Cramon, 1994; Sabe et al., 1992) have not been confirmed in small controlled studies (Sabe et al., 1995). The nootropic agent piracetam had a modest benefit in chronic aphasia (Huber, 1999), but the effects were lost when the medication was stopped (Kessler et al., 2000).
Recovery of Language after Stroke or Trauma in Adults
2006, Encyclopedia of Language & LinguisticsPhenomenology, neurobiology and pharmacotherapy of psychiatric syndromes following traumatic brain injury
2016, Traumatic Brain Injury: Diagnosis, Management and Long-Term Outcomes